書籍詳細

I. 化学療法の最近の進歩

P.8 掲載の参考文献

• 1) Petrylak DP, Tangen CM, Hussain MH, et al:Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (15):1513-1520, 2004.
  pubmed

• 2) Tannock IF, de Wit R, Berry WR, et al:Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (15):1502-1512, 2004.

• 3) Naito S, Tsukamoto T, Koga H, et al:Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer:a multicenter Phase II trial in Japan. Jpn J Clin Oncol 38 (8):365-372, 2008.

• 4) Sternberg CN, Yagoda A, Scher HI, et al:Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133 (3):403-407, 1985.
  pubmed

• 5) von der Maase H, Hansen SW, Roberts JT, et al:Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer:results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18 (17):3068-3077, 2000.
  pubmed

• 6) 日本泌尿器科学会編:膀胱癌診療ガイドライン2009年版. 医学図書出版, 東京, 2009.

• 7) Naito S, Yamamoto N, Takayama T, et al:Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era:a cooperative group report of 1463 patients. Eur Urol 57 (2):317-325, 2010.

• 8) Motzer RJ, Bacik J, Murphy BA, et al:Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20 (1):289-296, 2002.
  pubmed

• 9) Mead GM, Cullen MH, Huddart R, et al:A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer:a medical research council trial. Br J Cancer 93 (2):178-184, 2005.

• 10) Nonomura N, Oka D, Nishimura K, et al:Paclitaxel, ifosfamide, and nedaplatin (TIN) salvage chemotherapy for patients with advanced germ cell tumors. Int J Urol 14 (6):527-531, 2007.
  pubmed

P.17 掲載の参考文献

• 1) Engert A, Plutschow A, Eich HT, et al:Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 363 (7):640-652, 2010.

• 2) Miller TP, Dahlberg S, Cassady JR, et al:Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma. N Engl J Med 339 (1):21-26, 1998.
  pubmed

• 3) Coiffier B, lepage E, Briere J, et al:CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 (4):235-242, 2002.
  pubmed

• 4) Marcus R, Imrie K, Belch A, et al:CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105 (4):1417-1423, 2005.
  pubmed

• 5) Salles G, Seymour JF, Offner F, et al:Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA):a phase 3, randomised controlled trial. Lancet 377 (9759):42-51, 2011.

• 6) Kaminski MS, Tuck M, Estes J, et al:131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352 (5):441-449, 2005.
  pubmed

• 7) Wotherspoon AC, Doglioni C, Diss TC, et al:Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 342 (8871):575-577, 1993.
  pubmed

• 8) Yamaguchi M, Tobinai K, Oguchi M, et al:Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma:Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 27 (33):5594-5600, 2009.

• 9) Tsukasaki K, Utsunomiya A, Fukuda H, et al:VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma:Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 25 (34):5458-5464, 2007.

• 10) Yamamoto K, Utsunomiya A, Tobinai K, et al:Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 28 (9):1591-1598, 2010.
  pubmed

II. 抗癌剤の副作用を理解する(1) <一般的な副作用とその治療>

P.24 掲載の参考文献

• 1) de Boer-Dennert M, de Wit R, Schmitz PI, et al:Patient perceptions of the side-effects of chemotherapy:the influence of 5HT3 antagonists. Br J Cancer 76 (8):1055-1061, 1997.
  pubmed

• 2) 日本癌治療学会/編:制吐薬適正使用ガイドライン, 2010年5月[第1版], 金原出版, 東京.

• 3) Gralla RJ, Osoba D, Kris MG, et al Recommendations for the use of antiemetics:evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17 (9):2971-2994, 1999.

• 4) Hesketh PJ:Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 18 (2):163-173, 2000.
  pubmed

• 5) Pendergrass KB:Options in the treatment of chemotherapy-induced emesis. Cancer Pract 6 (5):276-281, 1998.
  pubmed

• 6) Kobayashi K, Bouscarel B, Matsuzaki Y, et al:pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells. Int J Cancer 83 (4):491-496, 1999.
  pubmed

• 7) Ikegami T, Ha L, Arimori K, et al:Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea. Cancer Res 62 (1):179-187, 2002.
  pubmed

III. ランチョンセミナー

P.34 掲載の参考文献

• 高知医療センター腫瘍内科ホームページ. http://www2. khsc. or. jp/department/kagakuryoho_a. htm

• 辻 晃仁:外来がん化学療法と地域連携. 治療学 41 (11):50-51, 2007.

• 辻 晃仁:高知県におけるがん化学療法の病診連携. Oncology Epoch 2:13-14, 2007.

• 辻 晃仁:Lower G. I. /Colon and Rectum Cancer大腸癌-大腸がんの地域連携パス. 癌と化学療去 37 (11):2067-2074, 2010.

• 辻 晃仁:病診連携の実際 高知医療センター腫瘍内科-クリニカルパスからはじめる医療連携. 外来癌化学療法 1 (1):48-57, 2010.

• 辻 晃仁:分子標的薬時代の副作用対策 (第1回)知っておきたい抗がん剤副作用. 日経メディカル 519:132-136, 2011.

• 辻 晃仁:化学療法を成功させる最大の武器は副作用対策-支持療法の上手な使い方. 日経メディカルオンライン, 癌Experts. http://medical. nikkeibp. co. jp/leaf/all/gakkai/sp/jspm2010/201007/516185. html

• 辻 晃仁:パスでできる! がん診療の地域連携と患者サポート, 大腸がん. 医学書院, 東京, 2009, pp. 57-64.

IV. 抗癌剤の副作用を理解する(2) <特殊な副作用とその治療>

P.44 掲載の参考文献

• 1) Hurwitz H, Fehrenbacher L, Novotny W, et al:Bevacizumab plus irinotecan, fluorouracil, and leucovorin in metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004.
  pubmed

• 2) Giantonio BJ, Catalano PJ, Meropol NJ, et al:Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer:results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544, 2007.

• 3) Dimetri GD, van Oosterom AT, Blackstein M et al:Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST. Proc Am Soc Clin Oncol 23:#4000, 2005.

• 4) Motzer RJ, Hutson TE, Tomczac P, et al:Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007.
  pubmed

• 5) Escudier B, Eisen T, Stadler WM, et al:Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007.
  pubmed

• 6) Lacouture ME, Mitchell EP, Piperdi B, et al:Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28:1351-1357, 2010.

• 7) Project Cetuximab (http://project-cetuximab. jp/default. aspx)

• 8) Grothey A:Oxaliplatin-safety profile:neurotoxicity. Semin Oncol 30 (4 Suppl 15):5-13, 2003.

V. 抗癌剤の副作用を理解する(3) <特殊な副作用とその対策・治療>

P.52 掲載の参考文献

• 1) 池田正孝, 左近賢人, 半田理雄・他:消化器外科手術におけるVTEの予防. 消化器外科 33 (9):1463-1469, 2010.

• 2) 江本 精:がんと凝固亢進の病態血液フロンティア 18(10):1547-1553, 2008.

• 3) Sakon M, Maehara Y, Yoshikawa H, et al:Incidence of venous thromboembolism following major abdominal surgery:a multi-center, prospective epidemiological study in Japan. J Thromb Haemost 4 (3):581-586, 2006.
  pubmed

• 4) Ota M, Nakamura M, Yamada N, et al:Prognostic significance of early diagnosis in acute pulmonary thromboembolism with circulatory failure. Heart Vessels 17 (1):7-11, 2002.
  pubmed

• 5) 肺血栓塞栓症/深部静脈血栓症 (静脈血栓塞栓症)予防ガイドライン作成委員会:肺血栓塞栓症/深部静脈血栓症 (静脈血栓塞栓症)予防ガイドライン. メディカルフロントインターナショナルリミテッド, 東京, 2004.

• 6) Sakon M, Kobayashi T and Shimazui T:Efficacy and safety of enoxaparin in Japanese patients undergoing curative abdominal or pelvic cancer surgery:results from a multicenter, randomized, open-label study. Thromb Res 125 (3):e65-70, 2010.
  pubmed

• 7) 左近賢人, 塚本泰司, 小林隆夫・他:腹部手術後静脈血栓塞栓症の予防に対するフォンダパリヌクスの臨床的評価. -間欠的空気圧迫法をベンチマークとした無作為化オープン試験-. 臨床医薬 24 (7):679-689, 2008.
  Medical*Online

• 8) Farge D, Durant C, Villiers S, et al:Lessons from French National Guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patients. Thromb Res 125 (Suppl 2):S108-116, 2010.

• 9) Debourdeau P, Kassab Chahmi D, Le Gal G, et al:2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer:report from the working group. Ann Oncol 20 (9):1459-1471, 2009.

• 10) Nalluri SR, Chu D, Keresztes R, et al:Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients:a meta-analysis. JAMA 300 (19):2277-2285, 2008.

• 11) Lyman GH and Kuderer NM:Prevention and treatment of venous thromboembolism among patients with cancer:the American Society of Clinical Oncology Guidelines. Thromb Res 125 (Suppl 2):S120-127, 2010.

P.66 掲載の参考文献

• 1) Yeh ET, Tong AT, Lenihan DJ, et al:Cardiovascular complications of cancer therapy:diagnosis, pathogenesis, and management. Circulation 109 (25):3122-3131, 2004.
  pubmed

• 2) 弦間昭彦:特集分子標的治療薬による特異的な副作用とその対策 肺毒性. 癌と化学療法 35 (10):1668-1670, 2008.

• 3) Azuma A and Kudoh S:High of drug-induced pneumonia in Japan. JMAJ 50 (5):405-411, 2007.

• 4) Swain SM, Whaley FS and Ewer MS:Congestive heart failure in patients treated with doxorubicin:a retrospective analysis of three trials. Cancer 97 (11):2869-2879, 2003.
  pubmed

• 5) Yeh ET and Bickford CL:Cardiovascular complications of cancer therapy:incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53 (24):2231-2247, 2009.
  pubmed

• 6) Floyd JD, Nguyen DT, Lobins RL, et al:Cardiotoxicity of cancer therapy. J Clin Oncol 23 (30):7685-7696, 2005.
  pubmed

• 7) Singal PK and Iliskovic N:Doxorubicin-induced cardiomyopathy. N Engl J Med 339 (13):900-905, 1998.
  pubmed

• 8) Barrett-Lee PJ, Dixon JM, Farrell C, et al:Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol 20 (5):816-827, 2009.
  pubmed

• 9) Ryberg M, Nielsen D, Cortese G, et al:New insight into epirubicin cardiac toxicity:competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst 100 (15):1058-1067, 2008.
  pubmed

• 10) Fumoleau P, Roche H, Kerbrat P, et al:Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer:French Adjuvant Study Group results. Ann Oncol 17 (1):85-92, 2006.

• 11) Guarneri V, Lenihan DJ, Valero V, et al:Long-term cardiac tolerability of trastuzumab in metastatic breast cancer:the M. D. Anderson Cancer Center experience. J Clin Oncol 24 (25):4107-4115, 2006.

• 12) Cardinale D, Colombo A, Sandri MT, et al:Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Cirulation 114 (23):2474-2481, 2006.

• 13) Kalay N, Basar E, Ozdogru I, et al:Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48 (11):2258-2262, 2006.
  pubmed

• 14) Lipshultz SE, Rifai N, Dalton VM, et al:The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351 (2):145-153, 2004.
  pubmed

• 15) Suter TM, Procter M, van Veldhuisen DJ, et al:Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 25 (25):3859-3865, 2007.

• 16) 吾妻安良太:薬剤性肺障害と人種差「グローバル時代の薬剤性肺障害-日本人の特殊性-」. Annual Review 呼吸器2009, 中外医学社, 東京, 2009, pp. 123-127.

• 17) ゲフィチニブ (イレッサ(R)錠250)の急性肺障害・間質性肺炎(ILD)に関する専門家会議最終報告, アストラゼネカ株式会社, 2003.

• 18) イレッサ(R)錠250プロスペクティブ調査 (特別調査) に関する結果と考察, アストラゼネカ株式会社, 2004.

• 19) 適正使用ガイド タルセバ(R)錠, 中外製薬株式会社

• 20) Sandler A, Gray R, Perry MC, et al:Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (24):2542-2550, 2006.
  pubmed